Studying at the University of Verona
Here you can find information on the organisational aspects of the Programme, lecture timetables, learning activities and useful contact details for your time at the University, from enrolment to graduation.
Study Plan
The Study Plan includes all modules, teaching and learning activities that each student will need to undertake during their time at the University.
Please select your Study Plan based on your enrollment year.
1° Year
| Modules | Credits | TAF | SSD |
|---|
One course among the followingOne course among the followingTwo courses among the followingThree courses among the following2° Year It will be activated in the A.Y. 2026/2027
| Modules | Credits | TAF | SSD |
|---|
| Modules | Credits | TAF | SSD |
|---|
One course among the followingOne course among the followingTwo courses among the followingThree courses among the following| Modules | Credits | TAF | SSD |
|---|
| Modules | Credits | TAF | SSD |
|---|
Two courses among:
- 2nd year - Molecular farming, Toxicology and applied pharmacology, Systems biology, Radioactivity and radiation protection - delivered in 2026/2027
- 1st and 2nd year - Biotechnology in neuroscience, Clinical proteomics - delivered in 2025/2026 and 2026/2027
A.A. 2025/2026: BIOTECHNOLOGY IN NEUROSCIENCE not available Legend | Type of training activity (TTA)
TAF (Type of Educational Activity) All courses and activities are classified into different types of educational activities, indicated by a letter.
Farming molecolare (2026/2027)
Teaching code
4S003677
Credits
6
Language
English
Scientific Disciplinary Sector (SSD)
BIO/15 - PHARMACEUTICAL BIOLOGY
Courses Single
Authorized
The teaching is organized as follows:
teoria
laboratorio
Learning objectives
The course aims to give the students notions of the use of recombinant systems for the production of biopharmaceuticals. In particular, the course will be focused on the biomolecular techniques used for the expression of recombinant proteins in prokaryotic and eukaryotic systems and the downstream processing and purification for their large-scale production. The different platforms used for the recombinant expression will be studied and compared. The different US and EU normative procedures for biopharmaceutical commercialization will be evaluated and compared. Specific examples of biopharmaceutical produced in recombinant systems and their therapeutic applications like for vaccines and antibodies will be discussed and studied.
